Navigation Links
Valeant Pharmaceuticals International, Inc. Announces Additional Information Regarding Continuance Proposal
Date:5/10/2013

LAVAL, Quebec, May 10, 2013 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) announced today that it has provided additional information related to the proposal to continue Valeant into British Columbia (the "Continuance") under the British Columbia Business Corporations Act (the "BCBCA"). The Continuance is being presented for shareholder approval at Valeant's 2013 Annual Meeting of Shareholders to be held on Tuesday, May 21, 2013.

If the Continuance is approved by shareholders, Valeant's current Articles and By-laws under the Canada Business Corporations Act will be replaced with a Notice of Articles and Articles (the "New Articles") under the BCBCA.  As previously described in the Management Proxy Circular and Proxy Statement dated April 11, 2013 (the "Proxy Statement"), the New Articles provide that shareholders seeking to nominate candidates for election as directors must provide timely written notice to Valeant in accordance with the terms of the New Articles (the "Advance Notice Provision").

Valeant has modified the Advance Notice Provision to provide that, in the case of an annual general meeting, a shareholder's notice must be received by Valeant no later than the close of business on the 50th day before the meeting date; provided, however, that if the date (the "Notice Date") on which first public announcement of the date of the annual general meeting was made is less than 60 days prior to the date of the annual general meeting, a shareholder's notice must be received by Valeant no later than the close of business on the 10th day following the Notice Date.

Valeant has supplemented its Proxy Statement to reflect the revision to the Advance Notice Provision.

About Valeant Pharmaceuticals International, Inc.

Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, neurology, and branded generics.  More information about Valeant Pharmaceuticals International, Inc. can be found at www.valeant.com.

Forward-looking Statements

This press release may contain forward-looking statements.  Forward-looking statements may generally be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," "target", or "continue" and variations or similar expressions.  These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements.  These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in the Company's most recent annual or quarterly report and detailed from time to time in Valeant's other filings with the Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference.  Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof.  Valeant undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual outcomes.

Additional Information and Where to Find It

Valeant filed the Proxy Statement with the U.S. Securities and Exchange Commission (the "Commission") on April 11, 2013, and a supplement to the Proxy Statement (the "Supplement") with the Commission on May 10, 2013.  The Proxy Statement and the Supplement are available for free at the Commission's website at www.sec.gov.  In addition, the Proxy Statement and the Supplement are available to all shareholders of Valeant at www.valeant.com.

(Logo: http://photos.prnewswire.com/prnh/20101025/LA87217LOGO)

Contact Information:

Laurie W. Little
949-461-6002
laurie.little@valeant.com


'/>"/>
SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Valeant Pharmaceuticals Provides Efinconazole Update
2. Valeant Pharmaceuticals Reports 2013 First Quarter Financial Results
3. Actavis Acquires Worldwide Rights for Valeants Metronidazole 1.3% Vaginal Gel
4. Valeant Pharmaceuticals International, Inc. Completes Tender Offer for Obagi Medical Products, Inc.
5. American Skin Association Announces New Member Of The Board J. Michael Pearson And New Education Council Member Ryan Weldon Of Valeant Pharmaceuticals International, Inc.
6. Valeant Pharmaceuticals International, Inc. Announces Receipt of Approval From the Antimonopoly Committee of Ukraine for its Previously Announced Acquisition of Obagi Medical Products, Inc.
7. Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance In The United States For Its Previously Announced Acquisition Of Obagi Medical Products, Inc.
8. Valeant Pharmaceuticals To Announce 2013 First Quarter Results On May 2, 2013
9. Valeant Pharmaceuticals Provides Update to Recent Event
10. Valeant Pharmaceuticals And Obagi Medical Products Agree On An Increased Offer Price Of $24.00 Per Share In Cash
11. Valeant Pharmaceuticals Announces Private Exchange Offer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2016)... , May 6, 2016  Hill-Rom Holdings, Inc. (NYSE: ... of Directors declared a fiscal year 2016 third quarter ... percent increase over the amount paid a year ago. ... record as of the close of business on June 10, ...    Hill-Rom is a leading global medical technology ...
(Date:5/5/2016)... Ltd. today reported initial promising results in animal trials of its Zika vaccine candidates. ... ... ... ... Pubmed. The analysis identified the highest gene Replikin Counts in Zika history back to ...
(Date:5/5/2016)... , First quarter 2016 adjusted diluted earnings per share ... , First quarter reported diluted (GAAP) loss per share ... revises 2016 financial guidance; now expects 2016 revenues to range ... non-GAAP earnings per share to range from $4.50 to $4.80 ... and manufacturing facility restructuring , Company expands ...
Breaking Medicine Technology:
(Date:5/6/2016)... ... May 06, 2016 , ... The National Association of Chain ... in Puerto Rico. Radio messages set to debut on Monday, May 9, and ... about ways to protect themselves and their unborn children from the effects of ...
(Date:5/6/2016)... ... May 06, 2016 , ... DrugDev President and CEO Ibraheem ... pharmaceutical industry conducts clinical trials. This month Ibs was named No. 20 on The ... he was honored as a Tech Disruptor by the Philadelphia Business Journal. , Stephanie ...
(Date:5/6/2016)... (PRWEB) , ... May 06, 2016 , ... ... Bluvault's Integration Service, their latest implementation service offering for global clients of Coupa ... Appterra ). , Bluvault’s Integration Service is a key component in the ...
(Date:5/6/2016)... ... 06, 2016 , ... From May 4 to 6, EarQ and ... opportunity to learn more about Signia’s technology and the successful business and marketing techniques ... priority to see practices succeed in this highly competitive industry,” said Ed Keller, president ...
(Date:5/6/2016)... ... May 06, 2016 , ... Multiple award winning plumbing ... operated for over 35 years. Maintaining core values of exceptional customer service, quality work ... made them a leading name in San Diego plumbing, and other services including heating ...
Breaking Medicine News(10 mins):